Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02821689|
Recruitment Status : Unknown
Verified June 2016 by Shuang Ye, RenJi Hospital.
Recruitment status was: Not yet recruiting
First Posted : July 1, 2016
Last Update Posted : July 1, 2016
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Interstitial lung disease (ILD) is a common complication of dermatomyositis (DM) with prevalence up to 65%, and is considered to be one of the determining factors of prognosis. Clinical amyopathic dermatomyositis (CADM), which is a special phenotype of DM, with characteristic cutaneous manifestations but no or only subclinical myopathy. Many studies, mainly from Asia, including ours, have demonstrated that these patients with CADM tend to develop a rapidly progressive ILD (RPILD) and have a poor response to conventional therapy, such as high-dose corticosteroids and immunosuppressants, leading to lethal outcome with a 6-month survival rate of less than 50%.
Pirfenidone, a new oral antifibrotic agent, has been approved for the treatment of idiopathic pulmonary fibrosis (IPF). Randomized controlled trials of pirfenidone in patients with IPF suggested that it could ameliorate pulmonary function decline and improve the progression-free survival. Its utility in connective tissue disease (CTD) related ILD has been implicated, but no evidence has yet demonstrated its efficacy. Therefore, the investigators conduct this study to evaluate the possible therapeutic effects of pirfenidone on RPILD associated with CADM.
|Condition or disease||Intervention/treatment||Phase|
|Dermatopolymyositis Interstitial Lung Disease||Drug: Pirfenidone||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||57 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Randomized Controlled Trial of Pirfenidone in Patients With Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis|
|Study Start Date :||July 2016|
|Estimated Primary Completion Date :||June 2017|
|Estimated Study Completion Date :||June 2018|
Eligible participants for clinical trial were randomized in a 2:1 ratio to pirfenidone/blank add-on. Pirfenidone was administered in three divided doses (200mg tid), and increased to the manufacturer's instructed target dose (600mg tid) over a 2-week period. Investigators were allowed to adjust the dose according to the participants' tolerance.
Pirfenidone was administered in three divided doses (200mg tid), and increased to the manufacturer's instructed target dose (600mg tid) over a 2-week period. The maximum dose was maintained throughout the study in patients who tolerated it.
No Intervention: Blank
Eligible participants for clinical trial were randomized in a 2:1 ratio to pirfenidone/blank add-on.
- changes of 12-month survival from the onset of ILD [ Time Frame: 12 months ]the effect of pirfenidone on improving the survival rate
- changes of high-resolution computed tomography (HRCT) scores from baseline at each visit [ Time Frame: one year ]the influence of pirfenidone on pulmonary interstitial changes
- changes of pulmonary function test from baseline at each visit [ Time Frame: one year ]the influence of pirfenidone on pulmonary function changes
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||16 Years and older (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Willingness of the subject to participate in the study, proven by signing the informed consent;
- All participants fulfilled the provisional diagnosis of CADM according to the modified Sontheimer's criteria.
- The course of ILD is longer than 3 months, but shorter than 6 months, presenting as increase in level of dyspnea, and worsening of fibrosis on pulmonary HRCT with >10% increase of HRCT score, and/or decrease in %FVC by >10% absolute value.
- Participants who are unwilling to sign the inform consent;
- The course of participants ever treated with biologics including basiliximab, or malignancy-associated CADM or overlapped with other CTD, or with alanine transaminase more than 2 times the upper normal limits;
- Pregnancy or lactation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02821689
|Contact: Shuang Ye, MDemail@example.com|
|Contact: Zhiwei Chen, MSfirstname.lastname@example.org|
|Department of Rheumatology, Ren Ji Hospital South Campus, School of Medicine, Shanghai JiaoTong University|
|Shanghai, Shanghai, China, 200001|
|Principal Investigator:||Shuang Ye, MD||RenJi Hospital|
|Responsible Party:||Shuang Ye, Executive Director, Dept. Rheumatology, Renji Hospital South Campus, RenJi Hospital|
|Other Study ID Numbers:||
|First Posted:||July 1, 2016 Key Record Dates|
|Last Update Posted:||July 1, 2016|
|Last Verified:||June 2016|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
Interstitial lung disease
Lung Diseases, Interstitial
Respiratory Tract Diseases
Nervous System Diseases
Connective Tissue Diseases
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents, Non-Steroidal